The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer: A long term follow up

Z. Hernádi, K. Szarka, Tamás Sápy, Zoárd Krasznai, G. Veress, Róbert Póka

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: Prognostic evaluation of HPV-16 genome status of the pelvic lymph nodes, the integration status of HPV-16 and p53 codon 72 polymorphism in cervical cancer. Design: Prospective cohort study. Setting: Department of Gynaecological Oncology, University of Debrecen, Hungary. Sample: Thirty-nine patients with HPV-16 positive cervical cancer. Methods: Primary tumour specimens of 39 cervical cancer patients with HPV-16 positive primary tumour were subjected to multiplex polymerase chain reaction using HPV-16 E1/E2, E7 and p53 codon 72 allele-specific primers. Pelvic lymph nodes of the same patients were also tested for the presence of HPV-16 DNA and for its integration status using HPV-16 E7 and E1/E2 ORF specific primers, respectively. Main outcome measures: Progression-free survival. Results: Metastatic lymph nodes carried HPV-16 DNA more frequently than nodes with no evidence of disease (100.0% vs 35.7%, P = 0.001). Cases with HPV-16 positive nodes had higher recurrence rate than those with HPV-16 negative nodes (42.9% vs 11.1%, P = 0.009). There was no difference between cases with and without histologically proven nodal disease with regard to integration status of HPV-16 DNA in the primary tumour (integrated 90.9% vs 71.4%, episomal 9.1% vs 21.4%, mixed 0% vs 7.1%) and p53 codon 72 polymorphism (Arg/Arg 54.5% vs 67.9%, Pro/Pro 0 vs 7.1%, Arg/Pro 45.5% vs 21.4%). Conclusion: Regardless of the presence of nodal metastasis, HPV-16 status of the nodes is a significant predictor of recurrent disease. HPV-16 integration status and p53 codon 72 genotype do not seem to have a bearing on disease outcome in cervical cancer with HPV-16 positive primary.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume110
Issue number2
DOIs
Publication statusPublished - Feb 1 2003

Fingerprint

Human papillomavirus 16
Uterine Cervical Neoplasms
Lymph Nodes
Genotype
Genome
Codon
DNA
Neoplasms
Hungary
Multiplex Polymerase Chain Reaction
Open Reading Frames
Disease-Free Survival

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{d091a4e774f447dd9b71536b700f1c7a,
title = "The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer: A long term follow up",
abstract = "Objective: Prognostic evaluation of HPV-16 genome status of the pelvic lymph nodes, the integration status of HPV-16 and p53 codon 72 polymorphism in cervical cancer. Design: Prospective cohort study. Setting: Department of Gynaecological Oncology, University of Debrecen, Hungary. Sample: Thirty-nine patients with HPV-16 positive cervical cancer. Methods: Primary tumour specimens of 39 cervical cancer patients with HPV-16 positive primary tumour were subjected to multiplex polymerase chain reaction using HPV-16 E1/E2, E7 and p53 codon 72 allele-specific primers. Pelvic lymph nodes of the same patients were also tested for the presence of HPV-16 DNA and for its integration status using HPV-16 E7 and E1/E2 ORF specific primers, respectively. Main outcome measures: Progression-free survival. Results: Metastatic lymph nodes carried HPV-16 DNA more frequently than nodes with no evidence of disease (100.0{\%} vs 35.7{\%}, P = 0.001). Cases with HPV-16 positive nodes had higher recurrence rate than those with HPV-16 negative nodes (42.9{\%} vs 11.1{\%}, P = 0.009). There was no difference between cases with and without histologically proven nodal disease with regard to integration status of HPV-16 DNA in the primary tumour (integrated 90.9{\%} vs 71.4{\%}, episomal 9.1{\%} vs 21.4{\%}, mixed 0{\%} vs 7.1{\%}) and p53 codon 72 polymorphism (Arg/Arg 54.5{\%} vs 67.9{\%}, Pro/Pro 0 vs 7.1{\%}, Arg/Pro 45.5{\%} vs 21.4{\%}). Conclusion: Regardless of the presence of nodal metastasis, HPV-16 status of the nodes is a significant predictor of recurrent disease. HPV-16 integration status and p53 codon 72 genotype do not seem to have a bearing on disease outcome in cervical cancer with HPV-16 positive primary.",
author = "Z. Hern{\'a}di and K. Szarka and Tam{\'a}s S{\'a}py and Zo{\'a}rd Krasznai and G. Veress and R{\'o}bert P{\'o}ka",
year = "2003",
month = "2",
day = "1",
doi = "10.1046/j.1471-0528.2003.01516.x",
language = "English",
volume = "110",
pages = "205--209",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer

T2 - A long term follow up

AU - Hernádi, Z.

AU - Szarka, K.

AU - Sápy, Tamás

AU - Krasznai, Zoárd

AU - Veress, G.

AU - Póka, Róbert

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Objective: Prognostic evaluation of HPV-16 genome status of the pelvic lymph nodes, the integration status of HPV-16 and p53 codon 72 polymorphism in cervical cancer. Design: Prospective cohort study. Setting: Department of Gynaecological Oncology, University of Debrecen, Hungary. Sample: Thirty-nine patients with HPV-16 positive cervical cancer. Methods: Primary tumour specimens of 39 cervical cancer patients with HPV-16 positive primary tumour were subjected to multiplex polymerase chain reaction using HPV-16 E1/E2, E7 and p53 codon 72 allele-specific primers. Pelvic lymph nodes of the same patients were also tested for the presence of HPV-16 DNA and for its integration status using HPV-16 E7 and E1/E2 ORF specific primers, respectively. Main outcome measures: Progression-free survival. Results: Metastatic lymph nodes carried HPV-16 DNA more frequently than nodes with no evidence of disease (100.0% vs 35.7%, P = 0.001). Cases with HPV-16 positive nodes had higher recurrence rate than those with HPV-16 negative nodes (42.9% vs 11.1%, P = 0.009). There was no difference between cases with and without histologically proven nodal disease with regard to integration status of HPV-16 DNA in the primary tumour (integrated 90.9% vs 71.4%, episomal 9.1% vs 21.4%, mixed 0% vs 7.1%) and p53 codon 72 polymorphism (Arg/Arg 54.5% vs 67.9%, Pro/Pro 0 vs 7.1%, Arg/Pro 45.5% vs 21.4%). Conclusion: Regardless of the presence of nodal metastasis, HPV-16 status of the nodes is a significant predictor of recurrent disease. HPV-16 integration status and p53 codon 72 genotype do not seem to have a bearing on disease outcome in cervical cancer with HPV-16 positive primary.

AB - Objective: Prognostic evaluation of HPV-16 genome status of the pelvic lymph nodes, the integration status of HPV-16 and p53 codon 72 polymorphism in cervical cancer. Design: Prospective cohort study. Setting: Department of Gynaecological Oncology, University of Debrecen, Hungary. Sample: Thirty-nine patients with HPV-16 positive cervical cancer. Methods: Primary tumour specimens of 39 cervical cancer patients with HPV-16 positive primary tumour were subjected to multiplex polymerase chain reaction using HPV-16 E1/E2, E7 and p53 codon 72 allele-specific primers. Pelvic lymph nodes of the same patients were also tested for the presence of HPV-16 DNA and for its integration status using HPV-16 E7 and E1/E2 ORF specific primers, respectively. Main outcome measures: Progression-free survival. Results: Metastatic lymph nodes carried HPV-16 DNA more frequently than nodes with no evidence of disease (100.0% vs 35.7%, P = 0.001). Cases with HPV-16 positive nodes had higher recurrence rate than those with HPV-16 negative nodes (42.9% vs 11.1%, P = 0.009). There was no difference between cases with and without histologically proven nodal disease with regard to integration status of HPV-16 DNA in the primary tumour (integrated 90.9% vs 71.4%, episomal 9.1% vs 21.4%, mixed 0% vs 7.1%) and p53 codon 72 polymorphism (Arg/Arg 54.5% vs 67.9%, Pro/Pro 0 vs 7.1%, Arg/Pro 45.5% vs 21.4%). Conclusion: Regardless of the presence of nodal metastasis, HPV-16 status of the nodes is a significant predictor of recurrent disease. HPV-16 integration status and p53 codon 72 genotype do not seem to have a bearing on disease outcome in cervical cancer with HPV-16 positive primary.

UR - http://www.scopus.com/inward/record.url?scp=0037332262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037332262&partnerID=8YFLogxK

U2 - 10.1046/j.1471-0528.2003.01516.x

DO - 10.1046/j.1471-0528.2003.01516.x

M3 - Article

C2 - 12618167

AN - SCOPUS:0037332262

VL - 110

SP - 205

EP - 209

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 2

ER -